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ABSTRACT (maximum 250 words, actual 249) 
Context: Both thyroid dysfunction and levothyroxine therapy (LT4) have been associated with bone loss, 
but studies on the effect of LT4 for subclinical hypothyroidism (SHypo) on bone yielded conflicting results.  
Objective: To assess the effect of LT4 treatment on bone mineral density (BMD), Trabecular Bone Score 
(TBS), and bone turnover markers (BTMs) in older adults with SHypo.  
Design and Intervention: Planned nested substudy of the double-blind placebo-controlled TRUST trial. 
Participants with SHypo were randomized to LT4 with dose titration vs. placebo with computerized mock 
titration.  
Setting and Participants: 196 community-dwelling adults over 65 years enrolled at the Swiss TRUST sites 
had baseline and 1-year follow-up bone examinations; 4 participants withdrew due to adverse events not 
related to treatment. 
Main Outcome Measures: One-year percent changes of BMD, TBS, and two serum BTMs (sCTX and P1NP). 
Student’s t-test for unadjusted analyses, and linear regression adjusted for clinical center and sex, were 
performed. 
Results: Mean age was 74.3y ± 5.7, 45.4% were women, and 19.6% were osteoporotic. The unadjusted 1-
year change in lumbar spine BMD was similar between LT4 (+0.8%) and placebo-treated groups (-0.6%; 
between-groups difference +1.4%: 95%CI -0.1 to 2.9, p=0.059). Likewise, there were no between-group 
differences in 1-year change in TBS (-1.3%: 95%CI -3.1 to 0.6, p=0.19), total hip BMD (-0.2%: 95%CI -1.1 to 
0.1, p=0.61), or BTMs levels (sCTX +24.1%: 95%CI -7.9 to 56.2, p=0.14), or after adjustment for clinical 
centers and sex. 
Conclusions: Over one-year levothyroxine had no effect on bone health in older adults with SHypo. 
Registration: ClinicalTrial.gov NCT01660126 and NCT02491008  
Key words: Subclinical hypothyroidism, Levothyroxine, Bone mineral density, Trabecular Bone Score, 
Bone markers   
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Précis: 
One year of levothyroxine for older adults with subclinical hypothyroidism does not affect bone health, 
as determined by bone mineral density, Trabecular Bone Score, or bone turnover markers. 
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Introduction 
The prevalence of subclinical hypothyroidism (SHypo), defined as an elevated thyrotropin (TSH) level with 
free thyroxine (FT4) within the reference range, increases with age, reaching >10% in men over 65 years 
and up to 21% in women ≥75 years [1, 2]. Increasing evidence suggests that treating SHypo with 
levothyroxine (LT4) does not confer clinical benefit [3, 4]. Although recent UK guidelines recommend 
against LT4 therapy except in very specific clinical conditions [5], others propose LT4 for adults with SHypo 
and a TSH > 10.0 mIU/L [6, 7] and up to nine out of ten women with SHypo and a TSH concentration 
between 5.5 and 10 mIU/L should be treated if some of these guidelines were followed [8].  
The deleterious effect of high thyroid function on bone, even at high-normal levels [9, 10] is well 
established. On the contrary, studies have found no association between SHypo and bone mineral density 
(BMD) changes [11, 12]; a meta-analysis of individual participant data found no association between SHypo 
and fracture risk [10]. Concerns have been raised on the impact of LT4 on bone [13], but data on the effects 
of LT4 replacement on bone in SHypo are scarce and conflicting. Three small (n=17 to 66) randomized 
clinical trials (RCT) showed either no difference [14, 15], or a small yet not clinically significant bone loss 
in the LT4-treated group [16]. Only one RCT analyzed bone turnover markers (BTMs) which increased 
transiently at 24 weeks in the LT4-treated group (between 7.7% for alkaline phosphatase, and 29.9% for 
sCTX), during a 48 weeks treatment with LT4 [16]. No study has analyzed the effect of levothyroxine 
substitution on Trabecular Bone Score, a textural index that evaluates pixel gray-level variations in the 
lumbar spine DXA image and provides an indirect index of trabecular microarchitecture, independent of 
bone density [17]. 
The Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism (TRUST) 
trial was a multicenter, international, double-blind parallel-group RCT of LT4 versus placebo [4, 18] and 
showed no apparent benefits of treatment on either primary objectives (Hypothyroid Symptoms or 
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Tiredness score) or secondary outcomes. Since there was scarce evidence on the effect of SHypo treatment 
by LT4 on bone health, we measured BMD, TBS and BTM in participants in Swiss centers, at baseline and 
follow-up of the TRUST trial to assess the effect of LT4 on bone. 
Methods 
Study population 
This nested study focused on skeletal outcomes of participants in the Swiss centers (Bern and Lausanne) 
of the TRUST trial (clinicaltrials.gov NCT02491008, NCT01660126) [4, 18]. It included community-dwelling 
individuals aged ≥65 years with persistent SHypo. Briefly as previously described [4], persistent SHypo was 
diagnosed by elevated TSH levels (≥4.6 and ≤19.9 mIU/L) on at least two measurements at least three 
months apart, and FT4 levels within the assay reference range. Exclusion criteria included use of LT4, 
antithyroid, amiodarone or lithium treatment within 12 months, thyroid surgery or radio-iodine, severe 
acute comorbidities, dementia, terminal illness or galactose intolerance [4]. For this bone study, among 
the 217 participants of the TRUST trial in Switzerland, 21 participants lacked measurements at 1-year 
follow-up. Four participants withdrew due to adverse events not related to treatment: three on the 
treatment arm, and one on the placebo arm. This analysis focused on the 196 participants who had 
baseline and 1-year follow-up DXA and/or BTMs values. Of these, 79 had no DXA exam at baseline or 1-
year, so there were 117 participants left with both DXA exams (Figure 1). Of the 196 participants, 6 had 
no BTMs measures at either baseline or 1-year follow-up for technical reasons, so 190 BTMs (sCTX and 
P1NP) were available for analysis.  
The trial was approved by the local Institutional Review Boards, and written, informed consent was 
obtained from all participants. The trial was conducted in accordance with the principles of the Declaration 
of Helsinki and Good Clinical Practice guidelines. 
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Intervention  
Briefly as previously described [4], treatment started with LT4 50 micrograms daily (25 micrograms in 
individuals < 50 Kg body weight or with known coronary heart disease). Dose was titrated in the active 
treatment group according to target TSH levels ≥0.4 and <4.6 mIU/L and a computerized mock titration in 
the placebo group.  
Clinical data 
We recorded baseline age, sex, current smoking and alcohol consumption, history of osteoporosis and 
diabetes mellitus, and all ongoing treatments. Bone-affecting treatments were classified in two categories. 
Beneficial treatments included anti-osteoporotics (raloxifene, bisphosphonates, denosumab or 
teriparatide), hormonal replacement therapy, and hydrochlorothiazide. Deleterious bone treatments 
included systemic or topical glucocorticoids, proton pump inhibitors, aromatase inhibitors, serotonin 
recapture inhibitors, and antiepileptic treatments. Incident fractures were prospectively recorded. 
BMD and TBS measures 
Participants had serial BMD and TBS measurements by dual energy X-ray absorptiometry (DXA) on a GEHC-
Lunar Prodigy (GEHC, Madison, WI, USA) at the Bern study site, and on a GEHC-Lunar iDXA (GEHC, Madison, 
WI, USA) at the Lausanne site. The two machines were cross-calibrated at the beginning of the trial for 
both BMD and TBS using the appropriate phantom, and benefited of a daily on-site quality control with 
the dedicated phantom supplied by the manufacturer. No statistical differences were observed between 
the two DXA machines; no longitudinal changes were observed during the study period. BMD measures 
Least Significant Change (LSC) values are: (i) for the GEHC-Lunar Prodigy, 0.030 g/cm2 at the lumbar spine 
(L1-L4) and 0.018 g/cm2 at the total hip; (ii) for the GEHC-Lunar iDXA, 0.028 g/cm2 at the lumbar spine (L1-
L4) and 0.033 g/cm2 at the total hip. Manufacturer recommendations were followed for DXA scans at 
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baseline and follow-up; quality assurance review was performed centrally at Lausanne for both the BMD 
and TBS parameters. BMD was measured at the lumbar spine (antero-posterior projection of L1 through 
L4) and the proximal femur (neck and trochanteric regions). Recorded images were reanalyzed for 5 
individuals because there were inconsistencies within vertebral readings. Individual vertebrae were 
excluded if there were fractures or degenerative changes, in accordance with the ISCD rules for excluding 
individual vertebrae [19] and if considered outliers (T-score ≥ +3.0 SD). The same vertebrae were excluded 
at different time points, and mean lumbar spine T-score was calculated as the mean of the included 
vertebra T-score values. Participants were excluded if only one vertebra remained for analysis. TBS of the 
spine was centrally assessed at Lausanne Center (blinded from clinical outcomes) with a modified version 
of TBS iNsight v3.0 which accounts for tissue thickness (Medimaps gro p, Geneva, CH) by Lausanne Center. 
Region of interest for TBS were (i) all vertebrae, because TBS is minimally affected by degenerative changes 
[20], and (ii) the same region used for spine BMD (e.g., the same included/excluded vertebrae). TBS LSC is 
3.88%. Left femur measurements were used unless precluded by prosthetic material.  
Bone turnover markers (BTMs) measurements 
Venous blood was drawn at any ime during the day and without regard to fasting status. The Bern 
University Hospital routine laboratory quantified serum concentration of bone biomarkers Procollagen 
type 1 N-terminal Polypeptide (P1NP), representing bone formation, and CrossLaps (sCTX), representing 
bone resorption, in blood samples at baseline and at 1-year follow-up using Roche Cobas© technology, 
from fresh samples (Bern participants) or from frozen samples (Lausanne participants). 
Statistical analysis 
We calculated we would need to include 375 participants to detect a difference in the change in total hip 
BMD as small as 1.3% over two years between groups, with power of 80% and two-sided alpha of 0.05, 
based on the annual bone loss observed in placebo treated individuals in several US trials [21].  
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Descriptive results (baseline data) are expressed as number of participants (percentage) or as mean ± 
standard deviation (SD). Between-group comparisons on the difference between 1-year follow-up and 
baseline values were performed using Student’s t-test for non-adjusted analyses, and linear regression 
adjusted for clinical site and sex to account for BMD differences resulting from DXA machines and gender, 
but unadjusted results were similar. Results are expressed as mean percent changes (95% confidence 
interval, 95%CI). Statistical significance was considered for p-values <0.05. All analyses were performed 
using Stata version 15 (StataCorp, College Station, TX) for Windows. 
Results 
The mean age at inclusion was 74.3 ± 5.7 years, 45.4% were women, and participants presented with a 
mean BMI of 27.5 ± 5.0 kg/m2 (Table 1). TSH was 6.4 ± 2.0 mlU/L and FT4 13.6 ± 1.9 pmol/L before 
randomization, corresponding to SHypo, which evolved to the euthyroid state at 1 year in the treatment 
arm but not in the placebo group (TSH 3.2 ± 1.5 vs. 5.6 ± 2.4; p<0.001). The characteristics of the 117 
participants with DXA exams are detailed by treatment group in Supplementary Table 1 [22]. At the 
baseline DXA exam, 19.6% of the participants were osteoporotic, and 20.5% were osteopenic according to 
the WHO definition based on the lowest T-score from lumbar spine, total hip or femoral neck [23]. Mean 
T-scores values were in the normal range at lumbar spine (-0.6 ± 1.5 SD) and total hip (-0.6 ± 1.2 SD), and 
in the osteopenic range at the femoral neck (-1.1 ± 1.1 SD). On the other hand, 26.5% had degraded TBS 
and 29.1% had partially degraded TBS, according to the thresholds defined in McCloskey et al [24]. The 
distribution of all parameters was balanced between groups (all p-values > 0.10) both in the whole study 
group and the DXA data subgroup, except for deleterious treatments (including systemic or topic 
glucocorticoids, proton pump inhibitors, aromatase inhibitors, serotonin recapture inhibitors, and 
antiepileptic treatments) in the DXA data subgroup, which were more frequent in LT4 treated participants 
(40.7%, vs. 22.4% of placebo treated participants, p-value=0.03).  
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Table 2 shows BMD and TBS values at baseline and 1-year follow-up by treatment group. One left femur 
value outlier due to femur anomalies was replaced by right femur readings; femur values were excluded 
for one participant as it was measured on different sides at each exam. Three participants had no hip 
image because of bilateral total hip prosthesis. At baseline, BMD in the placebo group was 1.122 ± 0.204 
g/cm2, 0.963 ± 0.166 g/cm2 and 0.890 ± 0.131 g/cm2 in lumbar spine, total hip and femoral neck 
respectively, and 1.133 ± 0.150 g/cm2, 0.980 ± 0.167 g/cm2, 0.908 ± 0.160 g/cm2 in the same sites in the 
LT4 treated group. At baseline, lumbar spine TBS was 1.325 ± 0.113 in the placebo group vs. 1.307 ± 0.968 
in the LT4 treated group.  
BMD percentage changes after one year were not statistically different in placebo and LT4-treated 
participants in non-adjusted analyses (Table 2, Figure 2) at lumbar spine BMD (-0.6% vs.+0.8%; between 
group difference +1.4%: 95%CI -0.1 to 2.9, p=0.059). Likewise, there were no between-group differences 
in 1-year change in total hip BMD (-0.2%: 95%CI -1.1 to 0.1, p=0.61) or femoral neck BMD (-0.2%: 95%CI -
1.8 to 1.4, p=0.82). Further adjustment for center and sex did not change the results (Supplementary Table 
2 [22]). Unadjusted lumbar spine TBS percentage changes after one year were not statistically different 
between the two groups either (-1.3%: 95%CI -3.1 to 0.6, p=0.19). We found similar results for TBS both in 
adjusted analyses, and independently of the included vertebrae (all vertebrae, or only those included in 
BMD analysis after application of ISCD guidelines). Results were similar after excluding participants 
receiving bone-affecting treatments. 
We assessed the effect of LT4 treatment vs placebo on BTMs: There was no statistically significant 
difference between groups, either in unadjusted (Table 3), or adjusted analyses (Supplementary Table 2 
[22]). The results were similar in sensitivity analyses by clinical site, or after excluding participants who 
were receiving bone affecting treatments (data not shown). 
In each group, 3 fractures were observed during follow-up, with no significant difference between groups. 
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Discussion 
Our study did not show any harmful effect of LT4 replacement for one year on bone health, which we 
assessed by measuring BMD, TBS and BTMs in community-dwelling adults aged ≥65 with SHypo. Our study 
is the largest randomized controlled trial for SHypo treatment to date, and no other study has analyzed 
SHypo treatment effect on bone microarchitecture as assessed by lumbar spine TBS. 
Three earlier RCTs analyzed the effect of LT4 treatment of SHypo in bone with conflicting results. Similar 
to our study, a double-blinded (n=31, 75% women, mean age: 68 years, follow-up 10 months) [14], and an 
unblinded (n=17 post-menopausal women, follow-up 14 months) [15] RCT did not find a significant 
difference in BMD change between LT4 and placebo treated individuals. Meta-analyses on the association 
of SHypo with fracture risk [10, 12] or BMD [11, 12] showed no difference in observed results when they 
included or excluded LT4-treated individuals, but did not analyze outcomes specifically in this group. Only 
the double-blinded RCT by Meier et al. reported a statistically but not clinically significant BMD loss [16] 
at the lumbar spine when it compared treatment to placebo (-1.15%) in 66 women (56.1 years, follow-up 
48 weeks). In this study TSH at follow-up (3.1 ±,0.3 mU/L) was similar to that of our study (3.2 ± 1.5 mU/L) 
but was higher at baseline (12.8±1.4 mU/L, as compared to 6.3±1.9); a stronger change in TSH could explain 
the observed results. Of note, 74% were postmenopausal; 37% of these women were on hormone 
replacement therapy (HRT), but interaction with estrogens was not analyzed. The transient increase in 
BTMs in the study by Meier et al. [16] may indicate that LT4 treatment restored bone turnover to the usual 
early menopause values in these almost two decades younger participants. Pines et al. reported that the 
beneficial effects of estrogen replacement on BMD were reduced when it was combined with LT4 
replacement therapy [25]. In our study, participants were older than in the Jaeschke et al. RCT [14], under 
half were women, and very few participants were on HRT (less than 6.9%) so we could not conduct a 
separate analysis. Adjustment by sex did not change the magnitude or the statistical significance of the 
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effect. Our results thus accord with those of two studies with a similar population [14, 15], suggesting LT4 
treatment for SHypo does not harm bone health after one year of treatment in individuals over 65; the 
current study results may however not apply to a younger population. 
Only three studies analyzed the effect of thyroid function on TBS. In two prospective cohorts of 
participants with thyroid cancer undergoing TSH suppressive therapy for 5 to 10 years [26, 27], excess LT4 
treatment had a deleterious effect on TBS only in women transitioning from pre- to post-menopause [26], 
and no effect in post-menopausal women at treatment initiation [26, 27]. But in a euthyroid cohort [28] 
high-normal free T4 levels, but not TSH values, were associated with low TBS only in post-menopausal 
women. In our study, as published, TBS changes are not associated to TSH values changes; the link to free 
T4 cannot be analyzed in detail, as it was not measured at follow-up.  
Our conclusions are reinforced by the absence of a signific nt difference in BTMs changes between both 
groups at one year. Meier et al. [16] obtained similar results by measuring different BTMs, including sCTX, 
finding no changes at 48 weeks. They did observe a transient increase (at 24 weeks) in treated adults, 
which they interpreted as restoration of normal remodeling levels that had been decreased in SHypo. We 
did not have earlier BTMs measures to evaluate this hypothesis. 
The greatest strengths of our trial were its double-blind RCT design and that it was the biggest RCT on 
SHypo and bone (past ones n=17 to 66). Among limitations, it may still be underpowered because we were 
able to include only 196 individuals. However, the point estimates in the current results went in the 
opposite direction to published ones, with a non-significant BMD increase under LT4 and a slight decrease 
under placebo, which makes it unlikely that we would have found different results with a larger sample. 
This trend for an eventual benefit of LT4 treatment on lumbar spine (p=0.06 for the difference in adjusted 
analysis) is most probably due to chance. Also the largest change included in the 95% confidence intervals 
is a gain of 2.9% spine BMD, or a loss of 4.0% for TBS, which makes it very unlikely that we have missed a 
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clinically important difference.  We might have been limited by the short follow-up period, although it was 
the longest blinded trial. Our study cannot address with appropriate power the effect in participants with 
more pronounced subclinical hypothyroidism, due to the low number of participants with TSH > 10 mUI/L,  
although this is also the case in the general population [1]. In our study TSH target values were < 4.6 mU/L 
as proposed for older persons [29], with some different expert opinions [7], and we cannot exclude that 
attaining lower TSH values might have a deleterious effect on bone health. Lumbar spine BMD baseline 
values were quite high in our participants, suggesting underlying degenerative changes that may interfere 
with the measures. However, degenerative changes do not affect femoral measures, neither lumbar spine 
TBS, which give similar results. Finally, sCTX pre-analytical conditions were not standardized (not done 
fasting in the morning) explaining the large range, but P1NP, which does not depend on these pre-
analytical conditions, did not change neither over time nor depending on treatment, confirming the 
absence of LT4 effect on remodeling at 1-year follow-up. 
Our results are reassuring in the context of the large number of individuals with SHypo treated with LT4, 
although this trend may change in the view of latest evidence and guidelines [5]. Only a large long-term, 
placebo-controlled trial will definitively determine if treatment of SHypo adversely affects bone health, 
and to the best of our knowledge such a trial is not ongoing or planned in the near future. Until long-term 
safety is ascertained, we suggest that physicians who wish to treat SHypo in their older patients prescribe 
the lowest thyroxine dose to achieve a clinical response and keep TSH within the normal range. 
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Figure 1: Flowchart of the nested TRUST bone study 
(Footnotes): 
FU: follow-up. AE: adverse events. DXA: Dual-X-ray-Absorptiometry. ISCD: International Society for 
Clinical Densitometry. BTMs: Bone Turnover Markers.  
 
Figure 2: One year change in BMD (bone mineral density, left) at LS (lumbar spine, continuous line), TH 
(total hip, dotted line) and FN (femoral neck, broken line), in placebo (diamonds) and LT4 (cross) treated 
patients. 
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Table 1: Characteristics of included participants, by treatment group  
 Placebo LT4 treated 
Sample size 96 100 
Bern study site 71 (74) 74 (74) 
Female 44 (45.8) 45 (45) 
Age (years) 74.2 ± 6.1 74.3 ± 5.3 
Weight (kg) 75.0 ± 14.8 78.2 ± 17.4 
Height (cm) 166.5 ± 8.9 167.1 ± 8.6 
BMI (kg/m2) 27.0 ± 4.5 27.9 ± 5.3 
Current smoking 8 (8.3) 8 (8.0) 
Excess alcohol consumption 11 (11.5) 8 (8.0) 
TSH (mUI/L)   
Baseline 6.5 ± 2.2 6.3 ± 1.9 
Median (IQR) 5.7 (5.2 – 7.1) 5.8 (5.1 – 6.8) 
Range 4.6 – 17.0 4.6 – 16.8 
Free T4 (pmol/L) 13.7 ± 1.8 13.5 ± 2.0 
GFR< 30 ml/min 3 (3.1) 3 (3.0) 
Osteoporosis history 13 (13.5) 13 (13.3) 
Diabetes history 10 (10.4) 16 (16.0) 
Ca supplemented 24 (25.0) 18 (18.0) 
Vitamin D supplemented 23 (24.0) 32 (32.0) 
Bone affecting treatments   
Anti-osteoporotic or HRT 11 (11.5) 5 (5.0) 
HTZC 12 (12.5) 11 (11.0) 
Systemic GC 3 (3.1) 2 (2.0) 
Deleterious 28 (29.2) 40 (40.0) 
LT4: Levothyroxine. BMI: body mass index. Excess alcohol consumption: more than 2 units per day. Ca:  
calcium. Anti-osteoporotic treatments: raloxifen, bisphosphonates, denosumab or teriparatide. HRT:  
hormonal replacement therapy. HTZC: hydrochlorothiazide. GC: glucocorticoids. Deleterious: proton  
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pump inhibitors, systemic or topic glucocorticoids, aromatase inhibitors, serotonin recapture inhibitors,  
antiepileptic treatments. Results are expressed as mean ± standard deviation for continuous variables  
and as number of participants (percentage) for categorical variables.   
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Table 2: BMD (g/cm2) and TBS values, and percentage changes after one year of treatment, by treatment 
group. 
 Placebo LT4 treated 
LT4 treated vs. 
Placebo 
p-value 
Lumbar spine, sample size 53 52   
BMD     
Baseline (g/cm2) 1.122 ± 0.204 1.133 ± 0.150   
1-year follow-up (g/cm2) 1.115 ± 0.206 1.140 ± 0.145   
Changes after one year 
treatment, non-adjusted (%) 
-0.6 (-1.8 to 0.6) 0.8 (-0.1 to 1.7) 1.4 (-0.1 to 2.9) 0.059 
TBS     
Baseline (unitless) 1.325 ± 0.113 1.307 ± 0.968   
1-year follow-up (unitless) 1.331 ± 0.098 1.299 ± 0.108   
Changes after one year 
treatment, non-adjusted (%) 
0.7 (-0.6 to 2.1) -0.5 (-1.9 to 0.8) -1.3 (-3.1 to 0.6) 0.19 
Femur, sample size 57 56   
Total hip     
Baseline (g/cm2) 0.963 ± 0.166 0.980 ± 0.167   
1-year follow-up (g/cm2) 0.960 ± 0.166 0.975 ± 0.173   
Changes after one year 
treatment, non-adjusted (%) 
-0.4 (-1 to 0.3) -0.6 (-1.2 to 0.1) -0.2 (-1.1 to 0.7) 0.61 
Femoral neck     
Baseline (g/cm2) 0.890 ± 0.131 0.908 ± 0.160   
1-year follow-up (g/cm2) 0.885 ± 0.131 0.901 ± 0.161   
Changes after one year 
treatment, non-adjusted (%) 
-0.5 (-1.3 to 0.2) -0.7 (-2.2 to 0.7) -0.2 (-1.8 to 1.4) 0.82 
LT4: Levothyroxine. Pl: placebo. n: sample size. BMD: bone mineral density. TBS: trabecular bone score. 
Results are expressed as mean BMD/TBS ± SD, or as mean percentage BMD/TBS change in one year (95% 
CI). Between-group comparisons performed using Student’s t-test. 
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Table 3: BTMs values, and non-adjusted percentage changes after one year of treatment, by treatment 
group. 
 Placebo LT4 treated 
LT4 treated vs. 
Placebo 
p-value 
Sample size 94 96   
sCTX     
Baseline (ng/L) 247.9 ± 148.9 244.7 ± 156.1   
1-year follow-up (ng/L) 252.0 ± 166.8 259.3 ± 149.9   
Changes after one year 
treatment (%) 
9.1 (-1.7 to 19.9) 
33.2 (3.1 to 
63.3) 
24.1 (-7.9 to 
56.2) 
0.14 
P1NP     
Baseline (µg/L) 39.5 ± 15.9 40.0 ± 25.1   
1-year follow-up (µg/L) 39.1 ± 17.9 41.8 ± 22.8   
Changes after one year 
treatment (%) 
2.3 (-4.1 to 8.8) 10.7 (3 to 18.3) 8.3 (-1.6 to 18.3) 0.10 
BTMs: bone turnover markers. LT4: Levothyroxine. Pl: placebo. sCTX: serum C-terminal Crosslinked  
Telopeptides. P1NP: Procollagen Type 1 N-terminal Propeptide. Results are expressed as mean sCTX/P1NP  
± SD, or as mean percentage sCTX/P1NP change in one year (95% CI). Between-group comparisons  
performed using Student’s t-test.  
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117 DXA exams baseline and 1 year FU
- 113 hip analysis
- 105 vertebrae analysis
21 excluded participants:
- Lost to FU (n=2)
- Death (n=2)
- Withdrawal (n=12; 4 for AE)
- No FU clinical data at 1 year (n=5)
196 included participants:
- 145 at Bern site
- 51 at Lausanne site
No DXA follow-up at 1 year:
Bern (n= 66)
- 46 no DXA exams* 
- 19 only 2 years FU
- 1 technical issue
*enrolled before bone substudy, home visits, refusal
Others:
- Lack hip DXA: no hip DXA image (n=3), different hip at 
baseline and FU (n=1)
- All vertebra excluded following ISCD guidelines (n=12)
Lausanne (n=13)
- 7 no DXA exams*
- 6 only 2 years FU
No BTMs values either at baseline or FU (n=6)
190 BTMs values baseline and 1 year FU
217 randomized participants in Switzerland:
- 162 at Bern site
- 55 at Lausanne site
Figure 1
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